Lantheus Holdings Inc
LNTH
View Detailed Chart
67.885USD
+0.075+0.11%
Close 01/27, 16:00（ET）Quotes delayed by 15 min
4.50BMarket Cap
27.56P/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+0.11%
5 Days
+3.04%
1 Month
+1.76%
6 Months
-6.92%
Year to Date
+2.01%
1 Year
-30.95%
View Detailed Chart
TradingKey Stock Score of Lantheus Holdings Inc
Currency: USD Updated: 2026-01-26Key Insights
Lantheus Holdings Inc's fundamentals are relatively very healthy, with industry-average ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 9 out of 205 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 82.92.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Lantheus Holdings Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
Lantheus Holdings Inc Highlights
StrengthsRisks
Lantheus Holdings, Inc. is a radiopharmaceutical-focused company engaged in delivering science to enable clinicians to find, fight and follow diseases to deliver patient outcomes. The Company classifies its products in three categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships. Radiopharmaceutical Oncology diagnostics and therapeutics help healthcare professionals (HCPs) find, fight and follow cancer, with a focus on prostate cancer. Precision Diagnostic products assist HCPs to find and follow diseases, with a focus on cardiology. Strategic Partnerships focus on enabling precision medicine through the use of biomarker solutions, digital solutions, and radiotherapeutic platforms. Its commercial products include PYLARIFY, DEFINITY, TechneLite, Neuraceq, and others. Its clinical candidates include LNTH-2404, NAV-4694, and PNT2002, among others. The Neuraceq (florbetaben F18 injection) is an F-18 PET imaging agent for Alzheimer’s disease.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 64.04% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 1.53B.
Overvalued
The company’s latest PE is 27.53, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 73.07M shares, decreasing 15.81% quarter-over-quarter.
Held by HACAX
Star Investor HACAX holds 32.60K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 1.29.
Analyst Rating
Based on
13
analysts
Buy
Current Rating
82.923
Target Price
+22.83%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Lantheus Holdings Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Lantheus Holdings Inc Info
Lantheus Holdings, Inc. is a radiopharmaceutical-focused company engaged in delivering science to enable clinicians to find, fight and follow diseases to deliver patient outcomes. The Company classifies its products in three categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships. Radiopharmaceutical Oncology diagnostics and therapeutics help healthcare professionals (HCPs) find, fight and follow cancer, with a focus on prostate cancer. Precision Diagnostic products assist HCPs to find and follow diseases, with a focus on cardiology. Strategic Partnerships focus on enabling precision medicine through the use of biomarker solutions, digital solutions, and radiotherapeutic platforms. Its commercial products include PYLARIFY, DEFINITY, TechneLite, Neuraceq, and others. Its clinical candidates include LNTH-2404, NAV-4694, and PNT2002, among others. The Neuraceq (florbetaben F18 injection) is an F-18 PET imaging agent for Alzheimer’s disease.
Ticker SymbolLNTH
CompanyLantheus Holdings Inc
CEOMarkison (Brian A)
Websitehttps://www.lantheus.com/
Related Instruments
-19.61%
-0.43%
-0.46%
-0.71%
-0.41%
+0.06%
-0.68%
+0.02%
+7.08%
-14.15%
-3.68%
-14.33%
+0.18%
+3.28%
-0.01%
-0.44%
-0.80%
+0.10%
+0.22%
+0.01%Popular Symbols
258.270
+2.860 (+1.12%)
188.520
+2.050 (+1.10%)
89309.880
-59.660 (-0.07%)
252.660
+11.810 (+4.90%)
3011.200
-8.170 (-0.27%)
430.900
-4.300 (-0.99%)
5210.650
+34.130 (+0.66%)
62.435
+0.009 (+0.01%)
1.200
-0.003 (-0.26%)
152.867
+0.489 (+0.32%)
